Thermo Fisher Scientific Launches Advanced Chromogenic Culture Media for Rapid Candida Detection, Including Drug-Resistant Candida auris
Thermo Fisher Scientific, a global leader in serving science, has announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar, innovative chromogenic culture media designed to enhance the speed and accuracy of detecting clinically significant Candida species, including the emerging global antimicrobial resistance (AMR) threat, Candida auris. These new media provide laboratories with a practical and highly efficient tool to improve the detection, differentiation, and management of Candida infections, supporting timely clinical intervention and strengthening infection prevention efforts worldwide.
The Growing Threat of Candida auris
Invasive fungal infections represent a significant and growing challenge for healthcare systems across the globe. Among these pathogens, Candida auris has emerged as a particularly concerning organism due to its multidrug-resistant nature, rapid transmissibility in healthcare environments, and association with severe clinical outcomes. Since its first identification, Candida auris has spread quickly across continents, leading to outbreaks in hospitals, long-term care facilities, and other healthcare settings.
The pathogen’s resistance to multiple antifungal treatments complicates patient management, increasing the risk of prolonged hospital stays, higher treatment costs, and elevated mortality rates. The need for rapid and accurate identification of Candida auris, as well as other clinically relevant Candida species, has become a pressing concern for microbiology laboratories. Screening and surveillance efforts are expanding, but conventional culture methods often require extended incubation periods and additional confirmatory testing, which can delay diagnosis and timely clinical response.
Introducing Brilliance Candida 2 Agar and Spectra Candida Agar
Thermo Fisher Scientific’s new chromogenic culture media address these critical challenges by offering clear, species-specific differentiation directly from primary cultures. Brilliance Candida 2 Agar and Spectra Candida Agar are designed to provide rapid visual identification of Candida species based on distinct color changes, significantly reducing the time required to obtain actionable results compared to traditional culture methods.
These media enable laboratories to accurately identify the most clinically important Candida species, including Candida auris, directly from patient samples. By providing faster differentiation, the media support more timely therapeutic decisions, enabling clinicians to initiate appropriate antifungal treatment sooner and implement infection control measures promptly.
Chris Armstrong, president of the microbiology business at Thermo Fisher Scientific, emphasized the importance of efficient diagnostic solutions in today’s healthcare landscape. “As new pathogens emerge that threaten patients and healthcare settings, it’s increasingly important that healthcare providers have effective screening strategies that don’t add complexity to routine laboratory workflows,” Armstrong said. “This new media delivers clear visual differentiation and faster results, helping laboratories respond confidently to emerging fungal threats and strengthening frontline defences against antimicrobial resistance, while maintaining efficiency and consistency.”
Benefits for Clinical Microbiology Laboratories
The launch of Brilliance Candida 2 Agar and Spectra Candida Agar provides several key advantages for laboratories:
- Rapid, Visual Differentiation of Species – The chromogenic properties of the media allow for direct identification of Candida species based on color reactions, enabling laboratory personnel to differentiate species without additional complex testing steps.
- Early Detection of Candida auris – By providing direct identification of Candida auris, these media help address one of the most pressing challenges in fungal diagnostics, supporting early intervention and outbreak management in healthcare settings.
- Shorter Incubation Times – The media reduce the time required to obtain results compared to conventional culture methods, enabling faster diagnostic workflows and more timely patient care.
- Operational Efficiency – Brilliance Candida 2 Agar and Spectra Candida Agar are designed to integrate seamlessly into routine laboratory workflows, with straightforward incubation and storage conditions that meet the practical requirements of laboratories of all sizes.
- Supports Antimicrobial Resistance Surveillance – By facilitating accurate identification and differentiation of Candida species, the media contribute to global efforts in AMR surveillance, outbreak preparedness, and infection prevention, ensuring laboratories can meet increasing testing demands without compromising quality.
- Consistent Performance Across Regions – Thermo Scientific Brilliance Candida 2 Agar is available for purchase in Europe, while Spectra Candida Agar is available in the United States. Both media are designed to provide equivalent performance while meeting the region-specific requirements of clinical laboratories.
Strengthening Global Healthcare Efforts
The introduction of these chromogenic media comes at a time when healthcare systems are under increasing pressure to detect, prevent, and manage invasive fungal infections more efficiently. With Candida auris outbreaks occurring in hospitals worldwide, the need for reliable diagnostic tools that enable rapid identification and differentiation of fungal pathogens has never been greater.
By delivering a practical, high-quality solution for Candida diagnostics, Thermo Fisher Scientific supports clinical microbiology laboratories in enhancing their workflow efficiency, reducing diagnostic delays, and ultimately improving patient outcomes. The media enable laboratories to perform screening, surveillance, and outbreak investigations with greater confidence, supporting both routine diagnostics and infection prevention strategies.
Moreover, these innovations align with global efforts to combat antimicrobial resistance. Rapid and accurate pathogen identification is a cornerstone of effective AMR management, enabling healthcare providers to target therapy appropriately, reduce unnecessary antifungal use, and implement infection control measures before infections spread further.
About Thermo Fisher Scientific
Thermo Fisher Scientific is a world leader in serving science, providing comprehensive solutions that empower scientists, clinicians, and laboratory professionals to make discoveries, improve patient outcomes, and address critical challenges in healthcare and research. The company’s extensive portfolio of microbiology culture media, diagnostic solutions, and laboratory products supports laboratories in achieving high standards of quality, accuracy, and efficiency, ensuring that the frontlines of healthcare are equipped to respond to emerging threats.
For laboratories and healthcare providers seeking more information about Thermo Fisher Scientific’s microbiology solutions, the full portfolio of culture media and diagnostic tools can be accessed through the company’s website: U.S. product page and Europe product page.
With the launch of Brilliance Candida 2 Agar and Spectra Candida Agar, Thermo Fisher Scientific reaffirms its commitment to supporting laboratories with innovative, practical solutions that enhance diagnostic speed, accuracy, and patient care, while advancing global efforts in antimicrobial resistance surveillance and infection prevention.
